Table 1. Baseline Characteristics.
| Characteristic | Patients, No. (%) | |
|---|---|---|
| Camrelizumab plus chemotherapy (n = 43) | Chemotherapy (n = 45) | |
| Age, median (IQR), y | 61 (54-65) | 61 (54-65) |
| Sex | ||
| Male | 34 (79.1) | 40 (88.9) |
| Female | 9 (20.9) | 5 (11.1) |
| Histologic characteristics | ||
| Squamous cell carcinoma | 27 (62.8) | 32 (71.1) |
| Adenocarcinomaa | 15 (34.9) | 11 (24.4) |
| Not specified or undifferentiated | 1 (2.3) | 2 (4.4) |
| ECOG performance status | ||
| 0 | 41 (95.3) | 43 (95.6) |
| 1 | 2 (4.7) | 2 (4.4) |
| Smoking | ||
| Nonsmoker | 12 (27.9) | 8 (17.8) |
| Former or current smoker | 31 (72.1) | 37 (82.2) |
| Clinical stage | ||
| IIIA | 30 (69.8) | 36 (80.0) |
| IIIB | 13 (30.2) | 9 (20.0) |
| Tumor, node, metastasis staging classification | ||
| T1N2M0 | 2 (4.7) | 4 (8.9) |
| T2N2M0 | 19 (44.2) | 18 (40.0) |
| T3N1M0 | 3 (7.0) | 4 (8.9) |
| T4N0M0 | 5 (11.6) | 5 (11.1) |
| T4N1M0 | 1 (2.3) | 5 (11.1) |
| T3N2M0 | 13 (30.2) | 9 (20.0) |
| PD-L1 expression level, % | ||
| <1 | 7 (16.3) | 8 (17.8) |
| ≥1 | 16 (37.2) | 11 (24.4) |
| Unknown | 20 (46.5) | 26 (57.8) |
Abbreviations: ECOG, Eastern Cooperative Oncology Group; PD-L1, programmed cell death ligand 1.
a
One patient presented with lung adenocarcinoma at baseline but with pleural mesothelioma on postoperative pathologic examination.